Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28331534 | 0.77 | CYP17A1 (0.47) | EGLN1CYP19A1CYP17A1MAPTMAPK1 | |
| SCHEMBL31489212 | 0.76 | CYP26A1 (0.34) | CYP26A1CYP19A1CYP17A1 | |
| SCHEMBL31489550 | 0.73 | CYP26A1 (0.30) | CYP26A1 | |
| SCHEMBL31489649 | 0.73 | CYP26A1 (0.30) | CYP26A1 | |
| SCHEMBL31489410 | 0.73 | CYP26A1 (0.30) | CYP26A1 | |
| SCHEMBL1243127 | 0.73 | KCNA5 (0.50) | CYP19A1HTTNPSR1 | |
| SCHEMBL3435309 | 0.70 | — | — | |
| SCHEMBL31489301 | 0.70 | CYP26A1 (0.30) | CYP26A1 | |
| SCHEMBL31489284 | 0.69 | NPC1 (0.32) | — | |
| SCHEMBL31489944 | 0.69 | NPC1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |